An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

The oncogenic BRAF inhibitor vemurafenib improves outcomes for patients with advanced BRAFV600 mutation-positive melanoma compared with cytotoxic chemotherapy. Vemurafenib is now approved for use in this patient population.

Source: European Journal of Cancer - December 20, 2018 Category: Cancer & Oncology Authors: James Larkin, Michael P. Brown, Ana M. Arance, Axel Hauschild, Paola Queirolo, Michele Del Vecchio, Paolo A. Ascierto, Ivana Krajsov á, Jacob Schachter, Bart Neyns, Claus Garbe, Vanna Chiarion Sileni, Mario Mandalà, Helen Gogas, Enrique Espinosa, Geke H Tags: Original Research Source Type: research